The Efficacy and Tolerability of Azilsartan in Mice With Left Ventricular Pressure Overload or Acute Myocardial Infarction

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Cardiovascular Pharmacology

• Publication date

  2013-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/FJC.0b013e318288a6d7PMID 23429590
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ramipril and Telmisartan Exhibit Differential Effects in Cardiac Pressure Overload-Induced Hypertrophy Without an Additional Benefit of the Combination of Both Drugs

  2013cited by this paper
• Myocardial recovery and the failing heart: myth, magic, or molecular target?

  2012cited by this paper
• Qiliqiangxin Inhibits the Development of Cardiac Hypertrophy, Remodeling, and Dysfunction During 4 Weeks of Pressure Overload in Mice

  2012cited by this paper
• Do angiotensin receptor blockers prevent myocardial infarctions as well as other initial therapies?

  2012cited by this paper
• The Angiotensin Receptor Blocker, Azilsartan Medoxomil (TAK-491), Suppresses Vascular Wall Expression of Plasminogen Activator Inhibitor Type-I Protein Potentially Facilitating the Stabilization of Atherosclerotic Plaques

  2011cited by this paper
• Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma

  2011cited by this paper
• Pathogenesis of aortic stenosis: not just a matter of wear and tear.

  2011cited by this paper
• Intracardiac renin-angiotensin system and myocardial repair/remodeling following infarction.

  2010cited by this paper
• Evidence for the efficacy of ARBs across the cardiovascular continuum

  2010cited by this paper
• Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study

  2010cited by this paper
• Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).

  2010cited by this paper
• TREATMENT OF PRIMARY ALDOSTERONISM: SHORT AND MIDDLE-TERM EFFECTS OF MEDICAL AND SURGICAL THERAPY IN PRIMARY HYPERALDOSTERONISM. EXPERIENCE ON 45 CASES: PP.18.187

  2010cited by this paper
• Effect of early versus late AT(1) receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits.

  2009cited by this paper
• A Profibrotic Effect of Plasminogen Activator Inhibitor Type-1 (PAI-1) in the Heart

  2009cited by this paper
• Recent advances in cardiovascular risk reduction: implications of ONTARGET.

  2009cited by this paper
• Gender‐Dependent Differences in Echocardiographic Characteristics of Murine Hearts

  2008cited by this paper
• The coronary arteries of the C57BL/6 mouse strains: implications for comparison with mutant models

  2007cited by this paper
• Insulin resistance increases PAI-1 in the heart.

  2006cited by this paper
• Induction of local angiotensin II-producing systems in stenotic aortic valves.

  2004cited by this paper
• Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies.

  2004cited by this paper
• Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

  2003influential reference
• Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy

  2001cited by this paper
• Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin.

  1999cited by this paper
• Angiotensin-converting enzyme inhibitors.

  1998cited by this paper
• Cardiac angiotensin converting enzyme overproduction indicates interstitial activation in renovascular hypertension.

  1995cited by this paper
• Angiotensin-converting enzyme inhibitors.

  1995cited by this paper
• GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction

  1994cited by this paper
• GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico.

  1994cited by this paper
• Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.

  1993cited by this paper
• Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure

  1993cited by this paper
• Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

  1992cited by this paper
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper
• Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System

  1991cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1988cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1987cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Depressed Myocardial Creatine Phosphokinase Activity Following Experimental Myocardial Infarction in Rabbit

  1970cited by this paper
• Modifications of a specific assay for hydroxyproline in urine.

  1967cited by this paper

• Azilsartan Modulates HMGB1/NF-κB/p38/ERK1/2/JNK and Apoptosis Pathways during Renal Ischemia Reperfusion Injury

  2023cites this paper
• Azilsartan ameliorates ventricular hypertrophy in rats suffering from pressure overload-induced cardiac hypertrophy by activating the Keap1-Nrf2 signalling pathway.

  2021cites this paper
• Insights into the actions of angiotensin-1 receptor (AT1R) inverse agonists: Perspectives and implications in COVID-19 treatment

  2021cites this paper
• Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.

  2016cites this paper
• Azilsartan Decreases Renal and Cardiovascular Injury in the Spontaneously Hypertensive Obese Rat

  2014cites this paper
• The Efficacy and Tolerability of Azilsartan in Obese Insulin-Resistant Mice with Left Ventricular Pressure Overload

  2013influential citation
• Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?

  2013cites this paper